Drug or treatment

Dupilumab clinical trials

• 39Clinical trials
• 1New in 30 days
• 25Countries

Newest trials

All recruiting trials (39)

• Dupilumab for Major Depressive Disorder

  This study tests whether dupilumab can engage immune targets in adults with major depressive disorder to see if it can help with depressive symptoms.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07908563

• See if IBI3027 works as well as Dupilumab for moderate to severe atopic dermatitis

  This study tests whether IBI3027 can help people with moderate to severe atopic dermatitis as effectively as Dupilumab injections.

  Recruiting Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Guangzhou, Guangdong · NCT07754786

• Dupilumab in COPD: Real-world Registry of Outcomes

  This registry tests how dupilumab works for COPD patients in everyday care and whether it lowers flare-ups and improves lung function and quality of life.

  Recruiting at 7 sites Sanofi · Indianapolis, Indiana and 6 other locations · NCT07612878

• Dupilumab added to standard COPD care after a flare-up

  This study tests whether adding dupilumab to usual COPD care after a severe flare requiring hospitalization can reduce the chance of another flare.

  Recruiting Phase 4 Regeneron Pharmaceuticals · Mullica Hill, New Jersey · NCT07587658

• Dupilumab's effect on anxiety and depression in moderate-to-severe atopic dermatitis

  This project will see if dupilumab reduces anxiety and depression in people with moderate-to-severe atopic dermatitis who are starting or recently started the medicine.

  Recruiting at 4 sites Sanofi · Doha and 6 other locations · NCT07467564

• Long-term follow-up of dupilumab treatment for COPD

  This project will follow adults with uncontrolled COPD and high blood eosinophils who start dupilumab in routine care to see if it is safe and improves symptoms and quality of life over 36 months.

  Recruiting at 28 sites Sanofi · Aix-en-Provence and 27 other locations · NCT07380711

• Dupilumab to induce remission in moderate, type-2 high asthma

  This trial tests whether dupilumab can help adults (18–79) with type-2 high moderate asthma who have had recent steroid-treated attacks achieve complete asthma control (remission).

  Recruiting at 3 sites Phase 3 Université de Sherbrooke · Nedlands, Western Australia and 4 other locations · NCT07309614

• Neoadjuvant immunotherapy with Dupilumab and Toripalimab for MSS colorectal cancer with resectable liver metastases

  This study tests a pre-surgery treatment combining dupilumab and toripalimab in adults with microsatellite-stable colorectal cancer that has liver metastases, to see if it’s safe and can lead to major tumor response.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07277322

• Dupilumab for early and long-term symptom relief and immune changes in prurigo nodularis

  This project will try dupilumab in adults with moderate-to-severe prurigo nodularis to see if it reduces itching and nodules and causes measurable immune changes over time.

  Recruiting UMC Utrecht · Utrecht, Utrecht · NCT07276425

• Stopping mepolizumab or dupilumab to see if nasal polyps stay in complete remission.

  This trial will test whether adults with well-controlled nasal polyps who have been on mepolizumab or dupilumab can safely stop the biologic and remain symptom-free.

  Recruiting at 6 sites Phase 4 Copenhagen University Hospital, Rigshospitalet · Copenhagen, Region H and 5 other locations · NCT07268313

• Dupilumab treatment for children with refractory eosinophilic gastrointestinal disorders

  We will try subcutaneous dupilumab injections in children with refractory EGIDs to see if symptoms, tissue eosinophils, and tolerability improve.

  Recruiting Children's Hospital of Fudan University · Shanghai · NCT07257835

• Dupilumab for young children with eosinophilic esophagitis (food-pipe inflammation)

  This study will test whether 24 weeks of dupilumab helps infants and toddlers with active eosinophilic esophagitis improve feeding and reduce esophageal inflammation.

  Recruiting at 13 sites Phase 3 Regeneron Pharmaceuticals · Phoenix, Arizona and 12 other locations · NCT07112378

• Dupilumab for nephrotic syndrome in children

  This study will try dupilumab to help children with steroid‑dependent or frequently relapsing nephrotic syndrome stay in remission and relapse less often.

  Recruiting at 2 sites Phase 2 National University Hospital, Singapore · Singapore, Singapore and 1 other locations · NCT07091175

• Dupilumab injections to reduce airway inflammation in adults 40–85 with COPD

  This trial will test whether dupilumab injections can reduce airway inflammation and mucus plugging and improve breathing, exacerbations, and quality of life in people aged 40–85 with moderate-to-severe COPD and evidence of type 2 inflammation.

  Recruiting at 84 sites Phase 4 Sanofi · Birmingham, Alabama and 84 other locations · NCT07053423

• Dupilumab for adults with COPD and high blood eosinophils in routine care

  This study will try dupilumab in adults with uncontrolled COPD and high blood eosinophils to see if it improves symptoms, quality of life, and safety over 24 months in routine care.

  Recruiting at 18 sites Sanofi · Auerbach and 17 other locations · NCT07052396

• DETACT — Dupilumab in severe eosinophilic asthma

  This project will try dupilumab in adults with severe Type 2 (eosinophilic) asthma to see if it reduces mucus plugging and changes airway cells, microbes, and metabolites.

  Recruiting Medical University of Vienna · Vienna, State of Vienna · NCT07025200

• Predicting smell recovery in patients with nasal polyps treated with dupilumab

  This study is trying to see if certain factors can help predict how well people with nasal polyps will recover their sense of smell after being treated with dupilumab.

  Recruiting Northwestern University · Chicago, Illinois · NCT06892704

• When to stop dupilumab in severe asthma

  This study tests whether stopping dupilumab in people with well-controlled, long-term severe asthma is as safe as continuing it for 24 months.

  Recruiting at 12 sites Phase 4 University Hospital, Toulouse · Toulouse, CHU de Toulouse and 28 other locations · NCT06818019

• Neoadjuvant Cemiplimab + Dupilumab in Early-Stage NSCLC

  This study tests whether giving cemiplimab with dupilumab before surgery can be safe and help shrink tumors in people with early-stage non-small cell lung cancer.

  Recruiting Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec and 1 other locations · NCT06743581

• Comparing dupilumab and topical corticosteroids for treating eosinophilic esophagitis

  This study is testing whether a new weekly injection called dupilumab works better than a daily swallowed medication for treating eosinophilic esophagitis in young people aged 12 to 25.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT06705387

• Long-term assessment of dupilumab for eosinophilic esophagitis in Germany

  This study is testing how well dupilumab works and how safe it is for people aged 12 and older with eosinophilic esophagitis in Germany over two years.

  Recruiting at 15 sites Sanofi · Aschaffenburg, Bavaria and 14 other locations · NCT06695897

• Effect of Dupilumab on Esophageal Muscle Function in Eosinophilic Esophagitis

  This study is testing if Dupilumab can help improve the muscle function in the esophagus of people with Eosinophilic Esophagitis.

  Recruiting Phase 4 University of California, San Diego · La Jolla, California · NCT06665971

• Treatment for locally advanced triple negative breast cancer using a combination of drugs

  This study is testing a new combination of drugs to see if it can safely help people with locally advanced triple negative breast cancer feel better and improve their chances of survival.

  Recruiting Early Phase 1 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06637306

• Using dupilumab to help patients with hypereosinophilic syndrome who still have symptoms

  This study is testing if adding dupilumab to the treatment of adults with hypereosinophilic syndrome can help reduce their ongoing symptoms.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06477653

• Investigating the effects of Dupilumab on nasal barrier function in chronic rhinosinusitis patients

  This study is testing if the medication Dupilumab can improve the nasal barrier function in people with chronic rhinosinusitis, especially those with nasal polyps.

  Recruiting Medical University of Vienna · Vienna, Austria · NCT06398873

• Investigating Dupilumab for Children with Prurigo Nodularis

  This study is testing if Dupilumab can help children with prurigo nodularis feel better and stay safe while using the medication.

  Recruiting at 15 sites Phase 3 Sanofi · Palo Alto, California and 14 other locations · NCT06293053

• Observing how adolescents with severe atopic dermatitis respond to dupilumab treatment

  This study looks at how well dupilumab treatment works for teenagers aged 12 to 17 with severe eczema over a year, focusing on their symptoms and quality of life.

  Recruiting at 9 sites Sanofi · Bologna and 8 other locations · NCT06192563

• Virtual reality game to reduce pain and anxiety during dupilumab injections

  This project will test whether a virtual reality game can reduce pain and anxiety for children aged 6–17 during dupilumab injections for moderate to severe atopic dermatitis.

  Recruiting at 2 sites St. Justine's Hospital · Montreal, Quebec and 1 other locations · NCT06182436

• Combination treatment for early-stage lung cancer

  This study is testing a combination of two medications, dupilumab and cemiplimab, to see if they can help people with early-stage lung cancer before surgery.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT06088771

• Using Dupilumab to treat children with Alopecia Areata

  This study is testing if Dupilumab can help children and teens with moderate to severe Alopecia Areata grow their hair back.

  Recruiting at 5 sites Phase 2 Icahn School of Medicine at Mount Sinai · Irvine, California and 4 other locations · NCT05866562

• Examining how dupilumab affects immune cells in atopic dermatitis

  This study is testing how the medication dupilumab affects immune cells in the skin of people with moderate to severe atopic dermatitis.

  Recruiting Phase 4 University of California, San Francisco · San Francisco, California · NCT05858619

• Using Dupilumab to Treat Itch in Genetic Skin Disorders

  This study is testing if dupilumab can help reduce severe itching and improve quality of life for people with genetic skin disorders.

  Recruiting Early Phase 1 Northwestern University · Chicago, Illinois · NCT05649098

• Treatment for moderate to severe alopecia areata using dupilumab

  This study is testing if a medication called dupilumab can help people with moderate to severe alopecia areata, which causes significant hair loss, to regrow their hair.

  Recruiting at 3 sites Phase 2 Icahn School of Medicine at Mount Sinai · Irvine, California and 2 other locations · NCT05551793

• Using Dupixent and UVB therapy for treating atopic dermatitis

  This study is testing if combining a medication called Dupixent with UVB light therapy can help people with moderate to severe eczema feel better.

  Recruiting Phase 4 Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey · NCT05285839

• Exploring how dupilumab works differently in various ethnic groups with atopic dermatitis

  This study is testing how well dupilumab works for people with atopic dermatitis from different ethnic backgrounds, like Caucasian, Asian, and African American, to see if their responses vary.

  Recruiting Phase 4 University of Michigan · Ann Arbor, Michigan · NCT05268107

• Treatment of chronic itching with dupilumab

  This study is testing if a medication called dupilumab can help adults with severe chronic itching feel better.

  Recruiting at 81 sites Phase 3 Sanofi · Bakersfield, California and 93 other locations · NCT05263206

• Blocking Interleukin-4Ra with Dupilumab to Reduce Staphylococcus in Nasal Polyps

  This study is testing if a medication called dupilumab can help people with nasal polyps reduce harmful bacteria and improve their overall nasal health.

  Recruiting Phase 4 University of Virginia · Charlottesville, Virginia · NCT05094570

• Improving sleep and skin symptoms in children with eczema using Dupilumab

  This study is testing if the medication Dupilumab can help improve sleep and skin symptoms in children aged 6 to 17 with moderate to severe eczema.

  Recruiting Phase 4 Northwestern University · Chicago, Illinois · NCT05042258

• Effect of Dupilumab on Mucociliary Clearance in Asthma Patients

  This study is testing if the medication dupilumab can help improve breathing by clearing mucus better in people with moderate to severe asthma.

  Recruiting Phase 4 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT04743791

Quick answers

How many clinical trials of Dupilumab are recruiting right now?

39, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 25 countries. The most sites are in United States (23 trials), Canada (5 trials), China (4 trials), France (4 trials), Germany (4 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 4: 11, Phase 2: 6, Phase 3: 5, Early Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →